Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC
Younger patients receiving afatinib or erlotinib showed better outcomes. For older patients, clinical factors such as functional status and body weight strongly influenced survival.
Authors
- Chung‐Yu Chen (ORCID: https://orcid.org/0000-0001-9002-7255)
- Shih‐Chieh Chang (ORCID: https://orcid.org/0000-0002-5481-9877)
- Cheng‐Yu Chang (ORCID: https://orcid.org/0000-0002-7196-3504)
- Yi-Chun Lai (ORCID: https://orcid.org/0000-0002-4673-7492)
- Yu-Feng Wei (ORCID: https://orcid.org/0009-0003-3634-3136)
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Taiwan University (TW)
- Far Eastern Memorial Hospital (TW)
- National Taiwan University Hospital (TW)
- National Yunlin University of Science and Technology (TW)
- Cardinal Tien College of Healthcare and Management (TW)
- National Yang Ming Chiao Tung University (TW)
- I-Shou University (TW)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-06-08
- DOI
- https://doi.org/10.1080/14796694.2025.2514422
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00